Therapeutic drug monitoring vs. pharmacogenetic testing in the context of elevated olanzapine concentrations and prior clozapine intolerability: a case study
Abstract Background Strong evidence for therapeutic drug monitoring exists for olanzapine and clozapine, however, olanzapine therapeutic drug monitoring is often underutilized. Evidence for pharmacogenomic-guided dosing of antipsychotics is not as robust, especially for cytochrome P450 1A2 metaboliz...
Bewaard in:
| Hoofdauteurs: | , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
BMC
2024-12-01
|
| Reeks: | BMC Psychiatry |
| Onderwerpen: | |
| Online toegang: | https://doi.org/10.1186/s12888-024-06319-5 |
| Tags: |
Geen labels, Wees de eerste die dit record labelt!
|